Table of Content

1. US Breast Cancer Drug Market Analysis
1.1 US Breast Cancer Market Overview
1.2 Current Market Scenario


2. Approved Breast Cancer Drugs by Class
2.1 Chemotherapeutic Drugs
2.2 Hormonal Therapy
2.3 Immunotherapeutic Drugs
2.3.1 Targeted Antibodies (ADC/Monclonal /Trispecific)
2.3.2 Immune Checkpoint Inhibitors
2.4 Kinase Inhibitors


3. New Emerging Therapies in Breast Cancer
3.1 Targeted Endocrine Therapy
3.2 Oral Selective Estrogen Receptor Degrader (SERD)
3.3 Immunotherapeutics through Cancer Vaccines
3.4 Tri-Specific NK Cell Engagers (TriKE)
3.5 Adoptive T Cell Therapy


4. US Breast Cancer Drug: Generic & Biosimilar Landscape
4.1 Current Scenario & Price Differential
4.2 Reimbursement Policy


5. US - Breast Cancer Clinical Trials Overview
5.1 By Drug Class
5.2 By Formulation
5.3 By Organization
5.4 By Patient Segment
5.5 By Phase
5.6 By Target



6. US - Breast Cancer Clinical Trials By Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-0
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered


7. US - Marketed Breast Cancer Drugs Clinical Insight


8. CDK 4/6 Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
8.1 Ribociclib (Kisqali)
8.2 Abemaciclib (Verzenio)
8.3 Palbociclib (Ibrance)


9. EGFR Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
9.1 Nertinib (Nerlynx)
9.2 Lapatinib (Tykerb)


10. Mitotic Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
10.1 Ixabepilone (Ixempra)
10.2 Eribulin (Halaven)
10.3 Paclitaxel-Protein Bound (Abraxane)
10.4 Paclitaxel (Taxol)
10.5 Docetaxel (Taxotere)


11. Aromatase Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
11.1 Anastrazole (Arimidex)
11.2 Letrozole (Femara)
11.3 Exemestane (Aromasin)


12. Hormonal Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
12.1 Raloxifene (Evista)
12.2 Tamoxifen (Soltamax)
12.3 Testosterone Cypionate (Depo-Testosterone)
12.4 Fluoxymesterone
12.5 Fareston (Toremifene)


13. Antimetabolite Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
13.1 Gemcitabine (Gemzar)
13.2 Capecitabine (Xeloda)
13.3 Flourouracil
13.4 Methotrexate


14. PARP Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
14.1 Olaparib (Lynparza)
14.2 Talazoparib (Telzenna)


15. Immunotherapy Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
15.1 Herceptin (Trastuzumab)
15.2 Avastin (Bevacizumab)
15.3 Perjeta (Pertuzumab)
15.4 Kadcyla (Ado-Trastuzumab Emtansine)
15.5 Tecentriq (Atizolizumab)
15.6 Keytruda (Pembrolizumab)

15.7 Enhertu (Fam-Trastuzumab Deruxtecan)
15.8 Phesgo (Hyaluronidase / Pertuzumab / Trastuzumab)
15.9 Herceptine Hylecta (Hyaluronidase / Trastuzumab)
15.10 Trodelvy (Sacituzumab Govitecan)


16. SERD for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
16.1 Fulvestrant (Faslodex) - Approval & Patent Dispute
16.2 Pricing & Dosage Analysis
16.3 Sales Analysis


17. Alkylating Agents for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight
17.1 Cyclophosphamide
17.2 Thiotepa


18. Other Breast Cancer Drugs - US Market Availability, Dosage, Patent & Price Insight
18.1 Tucatinib
18.2 Doxorubicin
18.3 Everolimus
18.4 Alpelisib (Piqray)


19. US Breast Cancer Market Insights for Ongoing Research Work & Development
19.1 Single Dose Radiotherapy Beneficial Over Other Conventional Breast Cancer
Treatment Options
19.2 Targeted Therapy to Emerge as Novel & Promising Opportunity for Breast
Cancer Treatment
19.3 UCLA Researchers Define the Lack of Predictive Biomarkers in Breast Cancer
Treatment
19.4 Development of Novel Model for Breast Cancer Patients by UCSF Researchers
19.5 Artificial Intelligence Applications Aids in the Development of Breast Cancer
Treatment


19.6 More Promising Survival Rate of the Breast Cancer Patients due to Surgery
Applications
19.7 Immunotherapy to Converge the Entire US Breast Cancer Market towards its
Applications
19.8 Estrogen Positive Breast Cancer Patients to Receive Potential Drug
Combination for Treatment
19.9 TNBC to Receive Special Attention for Novel Therapeutic Treatment Option
19.10 Rockefeller University Researchers to Introduce Telomere into Breast Cancer
Treatment
19.11 Veru Oncology Pharmaceuticals Expansion of Clinical Pipeline for Breast
Cancer
19.12 MIT Researchers to Revolutionize Breast Cancer Screening Methodologies by
Artificial Intelligence Applications
19.13 Researchers to Explore More Hidden Parameters for Breast Cancer Tumors
19.14 Environmental Factors Exposure Study on Breast Cancer Development
19.15 Targeted Therapy to Improve Breast Cancer Treatment in Mice Model


20. Research & Collaborations Advancing the US Breast Cancer Market at a Splendid Rata
20.1 Celcuity, Massachusetts General Hospital & Puma Biotechnology to Enter into
Collaboration for Advancing US Breast Cancer Market
20.2 US Based Pharmaceutical Company Pfizer to Collaborate with Japanese
Pharmaceuticals to Expand Breast Cancer Market
20.3 MacroGenics & EVERSANA to Collaborate for Launch & Commercialization of
Margetuximab Drug
20.4 New York Based Ibi & Atos Partners to Build Data for Breast Cancer Studies
20.5 NCCN & Pfizer to Collaborate for the Development of Metastatic Breast
Cancer Market
20.6 Alphamab Oncology & Pfizer to Work Together on Ibrance Drug for HER2
Positive Breast Cancer Patients
20.7 Pfizer & Zymeworks to collaborate for Evaluating ZW25 Combination Therapy
in Breast Cancer Patients
20.8 Pfizer & Flatiron Health to Expand Market for Breast Cancer Medicine
Development


21. US Breast Cancer Market Dynamics
21.1 Market Favorable Parameters
21.2 Market Challenges

22. US Breast Cancer Market Future Prospects

23. Competitive Landscape
23.1 Agilent Technologies
23.2 AstraZeneca
23.3 Bayer HealthCare Pharmaceuticals
23.4 Bristol-Myers Squibb
23.5 Eisai Co Ltd
23.6 Eli Lilly
23.7 Novartis
23.8 Onyx Pharmaceuticals
23.9 Orion
23.10 Perrigo
23.11 Pfizer
23.12 Roche